China will soon begin clinical trials with the drug for the covid-19 developed by the state pharmaceutical CNBG, based on the plasma of recovered patients and considered by the state press as the first of its kind in the world.
“Animal test results show that it can considerably relieve symptoms and damage caused by the coronavirus. It has just received approval from the State Drug Administration and clinical research will soon begin, ”CNBG Vice President Zhu Jingjin assured.
Through a message posted this Sunday on the Chinese social network’s WeChat account of the State Council’s Property Administration and Supervision Commission, Zhu detailed that “Plasma from patients recovered from covid (…) gives good results with critical and severe patients” from covid-19.
According to the source, this type of treatment causes a faster response for this type of at-risk patients.
However, Jiang Chulai of Jilin University clarified that “the actual effectiveness of a special drug continues to depend mainly on the results of clinical trials, More than the conclusions of the first stages “.
Another source also quoted by the state newspaper Global Times added that the drugs serve to alleviate the effects of the infection, but that prevention and vaccination remain the most effective forms to curb contagion and its effects.
CNBG and its parent company, state-owned Sinopharm, have developed for now two vaccines for inactivated virus covid-19 which are being used in countries such as Brazil, Indonesia, the United Arab Emirates or China itself.
Related news
The latest data from the National Health Commission of China show quand the Asian country has inoculated more than 2.1 billion doses of covid vaccines, Much of them, those developed by CNBG and Sinopharm
The company also stated that works on two vaccines for the covid of different technologies (One of them, of messenger RNA, such as those of the American pharmaceuticals Pfizer and Moderna) which, according to Zhu, have so far proved effective against the new strains of the SARs-CoV-2 coronavirus.